Ofatumumab - CISMeF

Preferred Label : Ofatumumab;

NCIt synonyms : HuMax-CD20, 2F2;

NCIt related terms : HuMax-CD20; Arzerra;

NCIt definition : A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.;

Alternative definition : NCI-GLOSS: A drug used to treat chronic lymphocytic leukemia (CLL) that has not gotten better with other chemotherapy. It is also being studied in the treatment of other types of cancer, including follicular non-Hodgkin lymphoma. Arzerra binds to CD20, a protein on the surface of normal B cells and most B-cell tumors. This may kill the cancer cells. It is a type of monoclonal antibody.;

UNII : M95KG522R0;

CAS number : 679818-59-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 679818-59-8 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : HuMax-CD20; Arzerra; Kesimpta;

Molecule name : GSK1841157;

Codes from synonyms : CDR0000559064; CDR0000537262; CDR0000660188; 364;

Details

Origin ID

C66952;

UMLS CUI

C1832027;

Automatic exact mappings (from CISMeF team)
- HUMAX-CD20 2F2 [MeSH concept]
- Ofatumumab [ICD-11 Extension code]
- ofatumumab [ATC Code]
See also inter- (CISMeF)
- Product containing ofatumumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Ofatumumab (substance) [SNOMED CT concept]
- Product containing ofatumumab (medicinal product) [SNOMED CT concept]
- Product containing ofatumumab in parenteral dose form (medicinal product form) [SNOMED CT concept]
- ofatumumab [ATC Code]
- ofatumumab [International Nonproprietary Name]
- ofatumumab [ATC Code]
- ofatumumab [MeSH Supplementary Concept]
- ofatumumab [MeSH concept]
Validated automatic mappings to BTNT
- ofatumumab [ATC Code]
chemical_or_drug_affects_cell_type_or_tissue
- B-Lymphocyte [NCIt concept]
chemical_or_drug_affects_gene_product
- B-Lymphocyte Antigen CD20 [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
chemical_or_drug_has_physiologic_effect
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD20 [NCIt concept]
is_component_of_chemotherapy_regimen
- Bendamustine/Ofatumumab Regimen [NCIt concept]
- EPOCH-O Regimen [NCIt concept]
- FC/Ofatumumab Regimen [NCIt concept]
- Ofatumumab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients